Therapeutic area intelligence for Lupus and Rheumatoid Arthritis with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

MK-1045 →

Recent signals(1)

ClinicalJune 24, 2026

Merck initiates trial for MK-1045 in lupus and rheumatoid arthritis patients

Merck Sharp & Dohme LLC is conducting a clinical study to evaluate the safety and tolerability of MK-1045 in patients with lupus and rheumatoid arthritis.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Lupus and Rheumatoid Arthritis →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.